Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

SLEEP REGULATORInvestigational

DSIP

Delta Sleep-Inducing Peptide · 10mg

Status

Investigational

Route

SubQ

Half-life

Short plasma half-life

Class

Neuropeptide

MechanismDelta Wave Sleep Modulation

Cohort44 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$55 USD/vial

À-la-carte: $60 USD/vial · Save 8%

Vials per allocation

Member total (1×)$55

À-la-carte total$60

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Nonapeptide supporting slow-wave sleep architecture. Indicated for sleep quality optimization without sedative mechanism.

Delta Sleep-Inducing Peptide · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

DSIP · Sleep Regulator

◆ Certificate of Analysis · DSIP

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot-specific COAs for DSIP are published with each batch release. Sample certificates available on request via partnerships@vivrelabs.com.

◉

Clinical Overview

DSIP

Delta Sleep-Inducing Peptide is a 9-amino-acid peptide originally isolated from rabbits exhibiting deep delta-wave sleep. Promotes slow-wave sleep architecture without acting through GABA pathways like traditional sedatives.

◷

Circadian Modulation

Influences delta-wave sleep and circadian regulation.

❖

Stress-Axis Effects

Modulates ACTH release; mechanism not fully elucidated.

◈

Evidence Status

Largely preclinical; distinct from sedative-hypnotics.

◈

Mechanism

How It Works

Mechanism not fully elucidated. Modulates ACTH release, supports circadian rhythm regulation, and influences delta-wave EEG activity.

Distinct from sedative-hypnotic mechanisms.

Mechanism & evidence - the honest frame

Sleep - honest evidence frame: DSIP (delta sleep-inducing peptide) is studied as an ACUTE, same-night sleep modulator - the idea being a tool for tonight’s sleep rather than a structural fix. Early human studies (Schneider-Helmert) reported longer sleep duration, higher quality and fewer interruptions in small insomniac samples. However, the better-controlled work tempers this: a double-blind study (Bes et al., Neuropsychobiology 1992, n=16) found the effects weak and partly attributable to a placebo-group change, concluding short-term DSIP is “not likely to be of major therapeutic benefit,” and modern reviews describe the clinical evidence as mixed and DSIP as investigational. So the honest read is: a plausible, well-tolerated acute sleep agent with real early signal but inconsistent controlled evidence - not a proven deep-sleep “force.” Mechanistically it interacts with GABAergic/glucocorticoid (GILZ/MAPK) systems. Contrast with Epithalon, which works on the circadian system over weeks rather than on a single night.

✚

Patient Bloodwork Guide

Bloodwork for Cognitive & Neuro Protocols

Nootropic / neuro - Semax, Selank, DSIP, Oxytocin, PT-141, Kisspeptin

These protocols target cognition, mood, stress regulation, and sleep. Their effects are mostly subjective and behavioral, so monitoring leans on functional and stress-axis markers more than a classic blood panel - the aim is to confirm benefit without disrupting your stress hormones or sleep architecture.

Incremental approach. These are low-dose, often short-course or as-needed protocols. Vivre tracks how you actually feel and function alongside a light marker panel, rather than chasing numbers - the subjective response is the primary signal here.

Stress axis & recovery

Cortisol rhythm (AM/PM)Confirms the protocol is calming the stress axis, not over-stimulating it. The key safety/efficacy marker for this group.

HRV (heart-rate variability)A non-blood measure of nervous-system balance and recovery - rises as stress regulation improves.

Brain & vascular health

HomocysteineElevated levels are linked to cognitive risk; a useful baseline to optimize.

BDNFA marker tied to neuroplasticity - context for neuro-supportive protocols (where testing is available).

Routine safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

BaselineCortisol rhythm, HRV, homocysteine, plus how you rate mood/focus/sleep.

Month 1HRV and a subjective check-in - is it helping, any over-stimulation?

Month 3Repeat cortisol rhythm and HRV to confirm a sustained, healthy direction.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Delta sleep-inducing peptide (nonapeptide)
Studied mechanism	Not fully elucidated; modulation of sleep architecture / stress axis studied
Human pharmacokinetics	Poorly characterised; very short plasma half-life reported
Evidence base	Sparse and inconsistent - historically contested
Form	Lyophilized powder, reconstituted under clinical protocol
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Mechanism not elucidated and evidence sparse - stated honestly rather than overclaimed. Educational only.

Clinical Literature

Peer-Reviewed References

Effects of delta sleep-inducing peptide (DSIP) on sleep of chronic insomniac patients (polysomnographic crossover study)

Schneider-Helmert D · 1985 · Acta Psychiatr Scand 1985;72(2):231–237

▾

Findings

Small double-blind, placebo-controlled crossover study (n=16) in chronic insomniac patients. Intravenous DSIP 25 nmol/kg administered before 3 of 5 polysomnographically-recorded nights. Reported higher sleep efficiency and shorter sleep latency under DSIP versus placebo, with no morning sedation. Important methodology notes - the authors' own conclusion: "the statistically significant effects were weak and in part could be due to an incidental change in the placebo group." Small cohort, IV administration (not the route Vivre carries), single-laboratory study. Best available human RCT data on DSIP, but should not be over-interpreted.

View on publisher ↗

DSIP-like material and its quantification in human plasma (early human sleep laboratory data)

Schneider-Helmert D, Schoenenberger GA · 1981 · Experientia / human sleep-laboratory series

▾

Findings

Earlier sleep-laboratory work characterising DSIP behaviour in human cohorts via polysomnography and biomarker tracking. The Karger reference is the broader human sleep-architecture body of work from the same group. Important methodology notes: 1970s–80s era research methodology; small samples; no replication in modern multi-site RCTs. The HPA-axis cortisol findings (DSIP modulates cortisol secretion patterns in MDD) are mechanistic, not outcome-based.

View on publisher ↗

DSIP has limited but real human RCT evidence - primarily the Schneider-Helmert 1985 polysomnography crossover trial (n=16, IV administration). The original authors themselves characterised the effects as "weak and in part could be due to an incidental change in the placebo group." No large-cohort modern Western RCT exists. Vivre acknowledges this honestly: the evidence is suggestive of mechanism (HPA-axis modulation, sleep-efficiency signal) but does not constitute the robust controlled human evidence patients should expect for an approved-class sleep medication. Allocation under physician supervision with explicit informed consent - and only after standard sleep-hygiene and approved-class options have been considered.

◇

Clinical Applications

Indications

Sleep architecture optimization
Stress-related sleep disturbance
Adjunct to circadian rhythm protocols

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

Short plasma half-life. Sleep-architecture effects, if confirmed, would be mediated through downstream neuromodulator pathways rather than direct peptide persistence.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Older preclinical research base. Limited modern clinical data.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

◎

Commonly Paired

Compounds Often Prescribed With DSIP

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Anxiolytic Peptide

Selank

Tuftsin Analog · 10mg

◆ sleep + anxiolytic

Selank's HPA-axis modulation pairs with DSIP's sleep architecture support - used in protocols where stress and sleep co-present as the primary limiters.

View Selank detail →

Pineal Regulator

Epithalon

Tetrapeptide · 10mg

◆ sleep - two timescales

DSIP and Epithalon address sleep on opposite timescales, which is why they are discussed together. DSIP is studied as an acute, same-night sleep modulator (early human studies reported longer, less-interrupted sleep, though better-controlled trials found the effect weak and inconsistent - it remains investigational). Epithalon is the opposite: no sedative effect at all, but reported in aging models to restore rhythmic, endogenous melatonin over weeks - a structural circadian repair rather than a nightly fix. Whether either is appropriate, and in what sequence, is a physician determination; Vivre publishes no sleep protocol.

View Epithalon detail →

READY TO PROCEED

Start with the Biological Audit

DSIP is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$55 USD/vial

DSIP · Member rate